Anyone know whether Epicentre 'an Illumina company' is discontinuing all 454 Nextera library products now that they are selling an updated Illumina version directly? Could not find any info on either site about it.
Unconfigured Ad
Collapse
X
-
The answer
From our sales rep: "I was able to confirm to day that this kit is being discontinued as of May 2012. The final decision was made yesterday and an email will be sent to all of the customer base within the next day or two. Regards..."
And probably the protocol is patented so no other company can take up the slack.
-
Nextera DNA Sample Prep Kits (Roche 454-Compatible) will be available for sale through Epicentre Customer Service until May 31, 2012, with final shipments required by June 30, 2012. This transition period will allow existing customers using these kits to complete ongoing projects without interruption.
Comment
Latest Articles
Collapse
-
by SEQadmin2
The immune system’s power comes from its genetic diversity, allowing myriad threats to be neutralized through first recognizing foreign antigens. That diversity is also what makes the immune system so difficult to study. Recent advances in sequencing technology and computational biology, however, are giving researchers new tools to understand immune responses and immune-related diseases in greater detail.
This convergence of genetics, immunology, and computation...-
Channel: Articles
09-01-2026, 05:41 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, 09-03-2026, 10:22 AM
|
0 responses
22 views
0 reactions
|
Last Post
by SEQadmin2
09-03-2026, 10:22 AM
|
||
|
Started by SEQadmin2, 09-02-2026, 12:32 PM
|
0 responses
23 views
0 reactions
|
Last Post
by SEQadmin2
09-02-2026, 12:32 PM
|
||
|
Started by SEQadmin2, 08-24-2026, 10:32 AM
|
0 responses
53 views
0 reactions
|
Last Post
by SEQadmin2
08-24-2026, 10:32 AM
|
||
|
Started by SEQadmin2, 08-20-2026, 11:17 AM
|
0 responses
51 views
0 reactions
|
Last Post
by SEQadmin2
08-20-2026, 11:17 AM
|
Comment